Client Result
Orrick Advises Bayer on Partnership with Ginkgo Bioworks
October.17.2022
October.17.2022
September.01.2022
The investment marks the first time MY DR NOW has received external capital.
July.25.2022
July.08.2022
June.27.2022
The primary focus of the acquisition is on the lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor.
June.06.2022
Returning investor OMERS Growth Equity led the round, which also included Fidelity Management & Research Company and other current investors.
June.06.2022
May.24.2022
Orrick advised South San Francisco-based biopharmaceutical company Catalyst Biosciences, Inc.
May.03.2022
January.21.2022
December.17.2021
September.24.2021